November 2009
Addition of Hydrazine to 4,7-Dihydro[1,2,4]triazolo[1,5-a]pyrimidines:
Hydrazine Derivatives of 4,5,6,7-Tetrahydro[1,2,4]triazolo[1,5-a]pyrimidine
1415
Scheme 3
40% of 3a. Anal. Calcd. for C12H16N6 (244.3): 59.00% C,
6.60% H, 34.40% N. Found: 58.87% C, 6.54% H, 34.35% N.
Compounds 2b,c and 3b were prepared in analogous way
from 1b and 1c, respectively. In case of 1c, the precipitate
formed contained only pure 2c.
A mixture of 2b and 3b was isolated in 96% yield and
contained, according to the 1H NMR data, 65% of 2b and
35% of 3b.
Pure compound 3b was isolated by careful crystallization of
the obtained mixture from dioxane-diethyl ether; m.p. 175–
177ꢁC. 13C NMR (DMSO-d6), for major stereoisomer: 14.5
(CH3), 44.1 (CH2), 55.6 (OCH3), 56.4 (CH), 114.1, 129.0 (m-
and o-CAr), 133.2 (i-CAr), 144.2 (C-5 of triazole), 148.6 (CH
of triazole), 155.1 (AC¼¼NA), 159.0 (p-CAr); for minor stereo-
isomer: 22.8 (CH3), 34.8 (CH2), 54.8 (OCH3), 55.6 (CH),
114.2, 128.6 (m- and o-CAr), 133.1 (i-CAr), 145.3 (C-5 of tria-
zole), 148.9 (CH of triazole), 155.4 (AC¼¼NA), 159.2 (p-CAr).
Anal. Calcd. for C13H18N6O (274.3): 56.92% C, 6.61% H,
30.64% N. Found: 56.83% C, 6.55% H, 30.71% N.
Compound 2c, m.p. 153–154ꢁC, was isolated in yield 73%.
13C NMR (DMSO-d6) d, ppm: 24.2 (CH3), 41.2 (C-6),
55.7 (C-7), 69.2 (C-5), 122.6 (p-CAr), 123.1 (o-CAr), 130.5
(m0-CAr), 134.6 (o0-CAr), 143.3 (i-CAr), 148.3 (m-CAr), 149.3
(C-2), 154.7 (C-3a). Anal. Calcd. for C12H15N7O2 (289.3):
49.82% C, 5.23% H, 33.89% N. Found: 49.69% C, 5.14% H,
33.97% N.
in DMF (1 mL) was refluxed for 30 min. The reaction mixture
was cooled to 20ꢁC, mixed with benzene (20 mL) and the pre-
cipitate formed was collected by filtration and crystallized
from DMF-methanol mixture.
4,7-Dihydro-5-methyl-7-(4-methoxyphenyl)[1,2,4]triazolo
[1,5-a]pyrimidine (1b). 4,7-Dihydro-5-methyl-7-(4-methoxy-
phenyl)[1,2,4]triazolo[1,5-a]pyrimidine (1b) was isolated with
yield 58% and melted at 215–216ꢁC (from mixture of DMF
1
and methanol). The H NMR signals were found in DMSO-d6
at 1.85 s, 3H (4-CH3), 3.70 s, 3H (OCH3), 4.50 d, 1H (6-H),
3
5.09 d, 1H, J ¼ 2.0 (7-H), 6.86 m, 2H (m-ArH), 7.11 m, 2H
(o-ArH), 7.51 s, 1H (2-H), 9.52 br.s, 1H (NH). The 13C NMR
signals were measured in DMSO-d6 at d, ppm: 18.9 (5-CH3),
55.8 (OCH3), 59.6 (C-7), 96.1 (C-6), 114.5 (m-CAr), 128.8 (o-
C
Ar), 132.4 (i- CAr), 135.3 (C-5), 149.6 (C-3a), 149.8 (C-2),
159.5 (p-CAr). The ei ms spectrum showed peaks at m/z
(%)242 (87) [Mþ], 227 (57) [Mþ-15], 214 (34) [Mþ-28], 200
(40) [Mþ-42], 135 (100) [Mþ-107]. Anal. Calcd. for
C13H14N4O (242.3): 64.45% C, 5.82% H, 23.13% N. Found:
64.39% C, 5.71% H, 23.05% N.
REFERENCES AND NOTES
[1] (a) Bossert, F.; Meyer, H.; Wehinger, E. Angew Chem 1981,
93, 755; (b) Goldmann, S.; Stoltefuß, J. Angew Chem 1991, 103, 1587.
[2] Desenko, S. M.; Komykhov, S. A.; Orlov, V. D.; Meier, H.
J Heterocycl Chem 1998, 35, 989.
4,7-Dihydro-5-methyl-7-(3-nitrophenyl)[1,2,4]triazolo[1,5-a]
pyrimidine (1c). Yield 52%; m.p. 249–250ꢁC (ethanol). 1H
NMR (DMSO-d6): 1.88 s, 3H (CH3), 4.61 m, 1H (6-H), 6.23
m, 1H (7-H), 7.60 s, 1H (2-H), 7.62–7.67 m, 2H (5,6-ArH),
8.03 m, 1H (2-ArH), 8.12–8.18 m, 1H (4-ArH), 9.73 br.s, 1H
(NH). 13C NMR (DMSO-d6): 19.0 (5-CH3), 59.3 (C-7), 94.9
(C-6), 121.9 (2-CAr), 123.5 (4-CAr), 131.0 (5-CAr), 133.5 (6-
CAr), 134.1 (C-5), 145.2 (1-CAr), 148.6 (3-CAr), 149.9 (C-3a),
150.4 (C-2). MS [EI, m/z (rel. %)]: 257 (78) [Mþ], 242 (25)
[Mþ-15], 210 (14) [Mþ-47], 135 (100) [Mþ-122], 128 (13)
[Mþ-129]. Anal. Calcd. for C12H11N5O2 (257.3): 56.03% C,
4.31% H, 27.22% N. Found: 55.92% C, 4.24% H, 27.18% N.
5-Methyl-7-phenyl-4,5,6,7-tetrahydro[1,2,4]triazolo[1,5-a]
pyrimidin-5-yl)hydrazine (2a) and 2-(3-hydrazono-1-phenyl-
butyl)[1,2,4]triazol-3-amine (3a). A solution of 1a [7] (1.40
g, 6.6 mmol) and 85% hydrazine hydrate (1.66 g, 30 mmol) in
dioxane (7 mL) was heated for 60 min and the solvent was
evaporated under reduced pressure. The residue was triturated
with diethyl ether (10 mL) and allowed to stand for 2 days.
The formed precipitate (1.51 g) was filtered off. It contained,
[3] (a) Desenko, S. M. Khim Geterotsikl Soedin 1995, 147; (b)
Desenko, S. M. Chem Heterocycl Compd (Engl Transl) 1995, 31, 125.
[4] (a) Tsuda, Y.; Mishina, T.; Obata, M.; Araki, K.; Inui, J.; Naka-
mura, T. (Yoshitomi Pharmaceutical Industries), U.S. Pat. 4,918,074
(1990); Chem Abstr 114, 81, 873 (1991); (b) Tsuda, N.; Mishina, T.; Obata,
M.; Araki, K.; Inui, A.; Nakamura, T. (Yoshitomi Pharmaceutical Indus-
tries), Jpn. Pat. 63,101,383 (1988); Chem Abstr 109, 128, 988 (1988); (c)
Desenko, S. M.; Orlov, V. D.; Lipson, V. V.; Gorbenko, N. I.; Pivovarevich,
L. P.; Ryndina, E. N.; Moroz, V. V.; Varavin, V. P. Khim Farm Zhurn
1995, 29, 37; Desenko, S. M.; Orlov, V. D.; Lipson, V. V.; Gorbenko, N. I.;
Pivovarevich, L. P.; Ryndina, E. N.; Moroz, V. V.; Varavin, V. P. Chem
Abstr 1996, 124, 239; (d) Atwal, K. S.; Moreland, S. Bioorg Med Chem
Lett 1991, 1, 291.
[5] Desenko, S. M.; Gladkov, E. S.; Nenaydenko, V. G.; Shish-
kin, O. V.; Shishkina, S. V. Khim Geterotsikl Soedin 2004, 71.
¨
[6] Abou El Ella, D.; Goßnitzer, E.; Wendelin, W. J Heterocycl
Chem 1996, 33, 373.
[7] Desenko, S. M.; Orlov, V. D.; Lipson, V. V. Khim Geterot-
sikl Soedin 1990, 1638; Chem Heterocycl Compd (Engl. Transl.) 1990,
26, 1362.
1
according to the H NMR data (Table 1) about 60% of 2a and
Journal of Heterocyclic Chemistry
DOI 10.1002/jhet